Caroli Disease

Caroli disease is a rare, congenital (present from birth) condition of the bile ducts inside the liver. In this disorder, parts of the large intrahepatic bile ducts become abnormally widened (saccular or fusiform dilatation). These widened ducts hold stagnant bile, which makes it easy for stones and infections to form. Caroli disease belongs to a family of “fibropolycystic” liver diseases that arise from an embryologic problem called ductal plate malformation (the normal circular sheet of cells that should remodel into healthy bile ducts does not remodel correctly). Because of this problem, people can develop recurrent cholangitis (bile duct infection), stones, and, over time, complications such as portal hypertension when fibrosis is present. NCBI+1

Caroli disease is a rare, birth-related (congenital) liver disorder where some of the intrahepatic bile ducts inside the liver are abnormally widened like sacs or tubes. Bile moves slowly in these enlarged ducts, so sludge and stones can form, infections can occur (recurrent cholangitis), and the liver may be injured over time. When the duct widening comes together with congenital hepatic fibrosis (scarring of the liver around the portal areas), it is called Caroli syndrome. People may have right-upper-belly pain, fever, jaundice, and sometimes portal-hypertension problems (varices, splenomegaly). The disease belongs to the fibropolycystic liver group and carries a higher-than-usual risk of cholangiocarcinoma (bile duct cancer). Management focuses on preventing infections, removing stones or blockages, supporting nutrition, and, in selected cases, liver resection or liver transplantation. PubMed Central+4NCBI+4Genetic and Rare Diseases Center+4

A closely related condition is Caroli syndrome, where the same bile-duct dilatations occur together with congenital hepatic fibrosis. Caroli syndrome is strongly linked with autosomal recessive polycystic kidney disease (ARPKD) due to variants in the PKHD1 gene; some patients have both liver and kidney findings. PubMed Central+2NCBI+2

Doctors sometimes group Caroli disease under the Todani classification of choledochal (bile duct) cysts as Type V cysts. In everyday words, “Type V” means multiple dilatations mainly inside the liver. When those dilatations coexist with congenital hepatic fibrosis, many authors use the term Caroli syndrome. NCBI+2Radiopaedia+2

Another important clinical fact: people with Caroli disease or Caroli syndrome have an increased lifetime risk of cholangiocarcinoma (bile duct cancer) compared with the general population, so careful long-term follow-up is needed. AASLD

Other names

• Congenital communicating cavernous ectasia of the intrahepatic bile ducts (a historical term that describes the cavern-like widened ducts that still connect to the biliary tree). NCBI

• Todani Type V choledochal cysts (classification name). NCBI

• Caroli syndrome (when duct dilatation coexists with congenital hepatic fibrosis). PubMed Central+1

Types

1. Caroli disease (isolated type).
   Dilatation of large intrahepatic bile ducts without congenital hepatic fibrosis. Patients often have bile stasis, stones, and recurrent cholangitis. Distribution can be segmental/localized to one part of the liver or diffuse across many segments. NCBI+1

2. Caroli syndrome (combined type).
   Dilatation of intrahepatic ducts with congenital hepatic fibrosis. These patients more often show signs of portal hypertension (splenomegaly, varices) and may progress to liver failure; ARPKD frequently coexists. PubMed Central+1

Causes

Caroli disease itself is congenital, so its root cause is abnormal bile-duct development before birth. Below are the core cause plus recognized contributors that explain why the disease appears and why complications occur later. I state each item in plain language.

1. Ductal plate malformation (primary cause).
   The primitive circular sheet of cells (ductal plate) fails to remodel into normal bile ducts, leaving segments dilated. NCBI

2. Genetic background involving PKHD1.
   Variants in PKHD1 (also central in ARPKD) are strongly associated with the spectrum that includes Caroli syndrome; genetics help explain familial clustering. NCBI

3. Autosomal recessive inheritance in many cases.
   Especially in Caroli syndrome, the trait often follows an autosomal recessive pattern (two altered gene copies). Genetic and Rare Diseases Center

4. Congenital hepatic fibrosis (when present).
   Abnormal development of the small bile ducts and portal tracts contributes to scarring and portal hypertension. AASLD

5. Association with ARPKD.
   The shared genetic/embryologic pathway links liver duct dilatation and kidney cysts in some patients. PubMed Central

6. Ciliopathy biology.
   ARPKD/PKHD1 disorders are “ciliopathies”; abnormal cilia signaling in cholangiocytes contributes to duct malformation and bile flow problems. (Inference from ARPKD GeneReviews and hepatorenal fibrocystic literature.) NCBI

7. Segmental embryologic variation.
   If the malformation affects only part of the liver, localized Caroli disease results; widespread involvement yields diffuse disease. AJR American Journal of Roentgenology

8. Bile stasis within dilated ducts.
   Stagnant bile promotes stone formation and infection; this is not the root cause but drives complications. NCBI

9. Heptatolithiasis (intraductal stones).
   Stones irritate and block ducts, causing repeated infections and worsening damage. NCBI

10. Recurrent cholangitis.
    Bacterial infections ascend from the intestine into poorly draining ducts, perpetuating inflammation. Genetic and Rare Diseases Center

11. Bile sludge and debris.
    Thick bile and debris in large ectatic ducts act like a plug, leading to pain, jaundice, and infection. National Organization for Rare Disorders

12. Strictures at duct junctions.
    Narrowings can form where normal and dilated ducts meet, further slowing bile flow. (Described within choledochal cyst disease spectrum.) NCBI

13. Portal tract changes in Caroli syndrome.
    Fibrosis around portal tracts increases resistance to flow in the portal system; this fuels splenomegaly and varices. PubMed Central

14. Coexisting choledochal cyst variants.
    Some patients show overlapping cystic disease patterns that complicate drainage. OAText

15. Recurrent partial obstruction from stones.
    Repeated partial blockages can expand ducts further over time. NCBI

16. Chronic inflammation and scarring.
    Ongoing infections and stones lay down scar tissue, making ducts stiff and narrow in places. NCBI

17. Risk for cholangiocarcinoma.
    Long-standing inflammation and stasis raise cancer risk; this is a serious late complication. AASLD

18. Bile composition changes.
    Stasis alters bile chemistry and encourages precipitation of pigment stones. (Supported broadly in choledochal cyst literature.) NCBI

19. Anatomical kinks or angulations at duct confluences.
    Abnormal geometry in dilated segments can trap bile. (Imaging literature shows irregular duct shapes.) AJR American Journal of Roentgenology

20. Superimposed infections with enteric organisms.
    Common biliary pathogens (e.g., E. coli, Klebsiella) promote attacks of cholangitis in stagnant ducts. (Clinical summaries for Caroli disease/syndrome.) Genetic and Rare Diseases Center

Note: Many items above (8–20) are contributors to disease expression and complications rather than stand-alone “causes.” The root cause is congenital ductal plate malformation with a strong genetic component. NCBI+1

Symptoms

1. Repeated right-upper-quadrant abdominal pain.
   Crampy or dull pain often worsens during infections or when a stone blocks bile flow. National Organization for Rare Disorders

2. Fever and chills.
   Typical during cholangitis attacks; fever may be high with shaking chills. Genetic and Rare Diseases Center

3. Jaundice (yellow eyes/skin).
   Happens when bile cannot drain and bilirubin builds up in the blood. National Organization for Rare Disorders

4. Dark urine and pale stools.
   Bilirubin goes into the urine instead of the intestine; stools may look clay-colored. National Organization for Rare Disorders

5. Itching (pruritus).
   Bile salts in the blood irritate the skin, especially when cholestasis is prolonged. Genetic and Rare Diseases Center

6. Nausea and vomiting.
   Common during acute cholangitis or painful obstruction episodes. National Organization for Rare Disorders

7. Fatigue and malaise.
   A general “run-down” feeling is frequent with chronic cholestasis or repeated infections. National Organization for Rare Disorders

8. Tenderness over the liver.
   The right upper abdomen may be tender when the ducts are inflamed. NCBI

9. Hepatomegaly (enlarged liver).
   The liver may enlarge from repeated inflammation and scarring. NCBI

10. Splenomegaly (enlarged spleen).
    Common in Caroli syndrome due to portal hypertension from hepatic fibrosis. PubMed Central

11. Easy bruising or nosebleeds.
    Can occur in advanced liver disease with low clotting factors or low platelets from hypersplenism. PubMed Central

12. Swelling of the abdomen (ascites) in advanced cases.
    Seen mainly in Caroli syndrome with portal hypertension and decompensation. PubMed Central

13. Recurrent cholestatic episodes since childhood or young adulthood.
    Many patients have symptoms from a young age; others present later. www.elsevier.com

14. Weight loss and poor appetite during prolonged illness or repeated infections. National Organization for Rare Disorders

15. Signs of biliary sepsis (confusion in severe episodes, low blood pressure).
    Requires urgent care when present. Genetic and Rare Diseases Center

Diagnostic tests

A. Physical examination (bedside observation and palpation)

1. General observation and vital signs.
   Doctors check fever, heart rate, blood pressure, and look for jaundice or scratching marks from itch. These basic findings help identify cholangitis and cholestasis quickly. NCBI

2. Abdominal palpation for RUQ tenderness.
   Gentle pressing over the right upper abdomen reveals liver tenderness during acute inflammation. NCBI

3. Liver and spleen size assessment.
   Clinicians feel and percuss to estimate hepatomegaly and splenomegaly, which point toward portal hypertension in Caroli syndrome. PubMed Central

4. Assessment for ascites and edema.
   Fluid wave or shifting dullness suggests advanced disease with portal hypertension in the combined (syndrome) form. PubMed Central

5. Look for stigmata of chronic liver disease.
   Spider nevi, palmar erythema, and muscle wasting, when present, suggest long-standing liver scarring. (Seen more in Caroli syndrome with fibrosis.) PubMed Central

B. Manual bedside tests/procedures

(In hepatology there are no special orthopedic-style “manual tests.” Here, “manual” refers to simple bedside maneuvers clinicians perform without machines.)

6. Murphy-type deep inspiration tenderness over RUQ.
   Exaggerated pain on inspiration during deep palpation can appear with acute biliary inflammation (not specific, but supportive in the right context). NCBI

7. Scratch test for liver size.
   A stethoscope is placed and the examiner lightly scratches the skin upward; change in sound helps outline liver edge, supplementing palpation/percussion. (A classic bedside maneuver in general hepatology.) Clinical technique reference common to liver exam.

8. Postural jaundice check and pruritus scoring.
   Clinicians document scleral icterus and track itch severity to judge cholestasis over time. Genetic and Rare Diseases Center

9. Bedside stool/urine color check.
   Pale stools and dark urine suggest obstructed bile flow. Simple observation supports the need for imaging. Genetic and Rare Diseases Center

C. Laboratory and pathological tests

10. Liver chemistries (ALT, AST, ALP, GGT, bilirubin).
    Caroli disease often shows a cholestatic pattern: raised ALP/GGT and bilirubin during attacks; transaminases can be mildly to moderately elevated. These labs help triage and monitor. NCBI

11. Complete blood count and inflammatory markers.
    Leukocytosis and elevated CRP support acute cholangitis; thrombocytopenia can signal portal hypertension/hypersplenism in Caroli syndrome. PubMed Central

12. Blood cultures during febrile episodes.
    Cultures identify bacteria (e.g., E. coli, Klebsiella) and guide antibiotics. Genetic and Rare Diseases Center

13. Serum electrolytes, renal function.
    Important in sick patients and in those with ARPKD overlap; kidney tests guide dosing and assess associated disease. PubMed Central

14. Genetic testing (PKHD1 and related panels).
    When history or imaging suggests Caroli syndrome/ARPKD, genetic testing helps confirm the underlying ciliopathy and supports family counseling. NCBI

15. Histopathology (when tissue is obtained).
    Biopsy is not routine, but when performed (e.g., for other reasons or at surgery), pathology shows ductal plate malformation; in Caroli syndrome, congenital hepatic fibrosis with expanded portal tracts is typical. AASLD

D. Electrodiagnostic / physiologic tests

(There is no liver-specific electrical nerve test for Caroli disease. In practice, “physiologic” or functional studies are used.)

16. Hepatobiliary scintigraphy (HIDA scan; nuclear medicine functional test).
    Although mainly used for gallbladder disease, HIDA can show poor bile flow or leaks; in Caroli disease it may support functional obstruction in complex cases, but MRCP is preferred for anatomy. NCBI

17. Elastography (transient or MR-based).
    Measures liver stiffness to estimate fibrosis severity—especially helpful in Caroli syndrome to noninvasively follow portal-fibrotic progression. www.elsevier.com

E. Imaging tests (the most decisive category in Caroli disease)

18. Ultrasound (first-line).
    Shows multiple anechoic, communicating ductal dilatations; may display the classic “central dot sign”—a bright dot inside a dark cystic area representing a portal vein radicle surrounded by dilated ducts. Radiopaedia+1

19. Contrast CT of the liver.
    Depicts segmental saccular duct dilatations and the central dot sign when portal radicles enhance; helps assess stones, abscesses, or mass lesions. AJR American Journal of Roentgenology

20. MRCP (magnetic resonance cholangiopancreatography)—the key test.
    Noninvasive MRI-based images clearly show communication with the biliary tree, the extent (localized vs diffuse), stones, and associated fibrosis—making MRCP a preferred definitive study for diagnosis and surgical planning. NCBI

(Additional procedural imaging used in selected cases: ERCP or percutaneous transhepatic cholangiography for therapy—stone extraction, stricture dilation—or when MRCP is inconclusive. These are invasive and used with caution.) NCBI

Non-pharmacological treatments (therapies & others)

1) Prompt treatment plan for acute cholangitis (care pathway).
When fever, pain, and jaundice suggest cholangitis, doctors quickly give IV fluids, blood cultures, and empiric antibiotics, then assess severity. If mild, antibiotics often control infection; if moderate or severe, urgent biliary drainage by ERCP or percutaneous catheter is advised. Early source control lowers sepsis risk, shortens stay, and prevents recurrent liver injury. This stepwise plan (resuscitation → antibiotics → drainage if needed) is a cornerstone in Caroli disease because stasis and stones make infections recur. Keeping a clear local plan helps patients present early and hospitals act fast. PubMed+2www.asge.org+2

Purpose: stop infection and protect the liver. Mechanism: antibiotics + mechanical decompression reduce bacterial load and pressure, restoring bile flow. PubMed

2) Scheduled ERCP-based clearance of stones and sludge.
Endoscopic retrograde cholangiopancreatography (ERCP) can cut the sphincter (sphincterotomy), mechanically extract stones, use baskets/balloons, and place plastic stents if complete clearance is not possible initially. In stented patients, planned exchanges every 3–6 months are recommended to reduce stent occlusion and cholangitis. This targeted endoscopic care is often repeated in Caroli disease due to recurrent stones. Esge+1

Purpose: maintain free bile flow and reduce infection risk. Mechanism: physical removal of obstructing material; stents bypass narrowed segments. Esge

3) Percutaneous transhepatic biliary drainage (PTBD) when ERCP fails.
If anatomy or tight strictures prevent ERCP, radiology-guided catheters can drain segments of the liver. This is particularly helpful in diffuse Caroli disease with multiple dilated segments that are hard to reach endoscopically. www.asge.org

Purpose: decompress infected ducts when ERCP is not feasible. Mechanism: image-guided catheter provides an exit path for bile to lower pressure and clear infection. www.asge.org

4) Hepatic resection for localized disease.
When Caroli disease affects one lobe or a limited segment, surgical removal of that diseased part can be curative, preventing recurrent stones and infections from that area and lowering cancer risk in that segment. Selection depends on localization and reserve. orpha.net

Purpose: remove the root source of stasis and stones. Mechanism: excision eliminates dilated ducts that trap bile and bacteria. orpha.net

5) Liver transplantation for diffuse disease or end-stage complications.
In extensive Caroli syndrome with recurrent cholangitis, portal hypertension, or progressive liver failure, orthotopic liver transplantation provides definitive treatment and markedly improves survival; careful kidney evaluation matters because of frequent hepato-renal associations. BioMed Central

Purpose: replace diseased liver and stop recurrent infections. Mechanism: new liver with normal ducts removes the anatomic problem. BioMed Central

6) Surveillance plan for cholangiocarcinoma risk.
Caroli disease carries an increased risk of cholangiocarcinoma (overall reported ~6–7% across cohorts). A practical plan uses periodic imaging (e.g., ultrasound or MRCP) and clinical review; any new weight loss, worsening cholestasis, or focal lesions should trigger expedited imaging and MDT review. PubMed Central+1

Purpose: detect cancer at a treatable stage. Mechanism: interval imaging catches early changes in duct walls/masses. PubMed Central

7) Nutrition with fat-soluble vitamin monitoring (A, D, E, K).
Chronic cholestasis impairs absorption of fat-soluble vitamins. Annual checks and proactive supplementation improve bone health, vision, clotting, and neurologic function. Water-miscible formulations or parenteral vitamin K before invasive procedures are often used. PubMed Central+2AASLD+2

Purpose: prevent deficiency complications. Mechanism: replace vitamins that are poorly absorbed when bile acids are low in the gut. PubMed Central

8) Bone health program (calcium/vitamin D + DEXA when indicated).
Cholestatic disorders raise osteoporosis risk. Baseline and periodic DEXA plus adequate calcium/vitamin D and weight-bearing activity can prevent fractures; manage additional risks (steroids, malnutrition). AASLD

Purpose: reduce fracture risk. Mechanism: optimize mineralization and monitor bone density changes early. AASLD

9) Vaccinations and infection-prevention hygiene.
Hepatitis A and B vaccination and up-to-date routine vaccines reduce preventable liver or systemic infections; hand hygiene and safe food/water habits help people who may need repeated procedures and sometimes antibiotics. (General hepatology prevention guidance extrapolated to Caroli disease.) NCBI

Purpose: protect a vulnerable liver and reduce procedure-related infections. Mechanism: active immunization lowers viral hepatitis risk; hygiene reduces bacterial exposure. NCBI

10) Pruritus management ladder without drugs first.
Keep skin moisturized, avoid hot showers, use loose cotton clothing, and consider brief UVB phototherapy if available. These comfort measures can lower itch intensity before or alongside medications. PubMed Central

Purpose: improve sleep and quality of life. Mechanism: barrier support and sensory modulation reduce itch-scratch cycle. PubMed Central

11) Hydration and fever plan during intercurrent illness.
Dehydration thickens bile; fever suggests infection. Patients should have a simple “action plan”: oral fluids, check temperature, seek care early if fever or jaundice appears—this reduces delays that worsen cholangitis. PubMed

Purpose: prevent bile stasis and late presentations. Mechanism: adequate fluid keeps bile less viscous; early triage catches infection earlier. PubMed

12) MRCP-based mapping before interventions.
Pre-procedure MRCP helps define which segments are dilated or strictured so endoscopists or surgeons can target therapy efficiently and avoid missing isolated pockets. JAJ Gastro Hepato

Purpose: plan precise therapy. Mechanism: noninvasive duct imaging guides selective drainage/resection. JAJ Gastro Hepato

13) Avoid unnecessary ERCP when not indicated.
Because ERCP has complication risks, noninvasive imaging (US/MRCP/EUS) is preferred for diagnosis; ERCP is best reserved for therapy (stone extraction, drainage). SGGSSG

Purpose: lower iatrogenic pancreatitis and infections. Mechanism: reserve ERCP for interventions rather than diagnosis. SGGSSG

14) Education on alarm symptoms and when to come to hospital.
Teach patients to recognize fever with chills, new jaundice, confusion, severe abdominal pain, or rigors as urgent signs of cholangitis/sepsis; clear instructions reduce delay to life-saving drainage. PubMed

Purpose: early escalation. Mechanism: patients trigger the care pathway quickly. PubMed

15) Multidisciplinary follow-up (hepatology, endoscopy, radiology, surgery, transplant).
Complex anatomy, recurrent stones, and cancer risk require shared decisions and periodic re-review of imaging and symptoms in MDT clinics. NCBI+1

Purpose: coordinate staged care and timing of surgery or transplant. Mechanism: pooled expertise improves outcomes. orpha.net

16) Antibiotic stewardship protocol for recurrent infections.
Culture-guided choices, shortest effective courses, and documentation of prior organisms reduce resistance in people who may need repeated antibiotics. Align with Tokyo Guidelines severity and local antibiogram. Darmzentrum Bern

Purpose: maintain antibiotic effectiveness. Mechanism: narrow and time-limit therapy based on evidence. Darmzentrum Bern

17) Post-stent care and scheduled exchange reminders.
Patients with plastic biliary stents should have a calendar (3–6 months) for stent exchange; overdue stents often clog and cause cholangitis. Esge

Purpose: prevent stent-related infections. Mechanism: preemptive exchange before occlusion. Esge

18) Lifestyle: balanced diet with adequate protein and small frequent meals.
Chronic cholestasis can reduce appetite; small meals with adequate protein and energy prevent muscle loss while vitamin-adjusted fat intake avoids steatorrhea. Hepatology Journal

Purpose: maintain strength and healing. Mechanism: match nutrition to malabsorption pattern. Hepatology Journal

19) Portal-hypertension screening in Caroli syndrome.
If there is congenital hepatic fibrosis (Caroli syndrome), screen for varices and manage splenomegaly/low platelets per standard portal-hypertension practice. AASLD

Purpose: prevent bleeding. Mechanism: treat varices and monitor progression. AASLD

20) Psychosocial and caregiver support.
Recurrent infections, procedures, and uncertainty about surgery or transplant are stressful. Counseling and patient groups improve coping, adherence, and timely care-seeking. National Organization for Rare Disorders

Purpose: sustain long-term self-management. Mechanism: reduce anxiety and improve health behaviors. National Organization for Rare Disorders

---

Drug treatments

Important: Drug choices and doses must be individualized by the treating clinician based on cultures, severity, kidneys, and local resistance. Below are commonly used evidence-aligned options and pruritus/cholestasis agents; some uses are off-label in Caroli disease and are noted.

1) Ursodiol (ursodeoxycholic acid).
Class: hydrophilic bile acid. Why: improves bile composition/flow in cholestatic disorders and may reduce stones/sludge; widely used in fibropolycystic disease although on-label indication is PBC. Dose (adult PBC label): 13–15 mg/kg/day in 2–4 doses with food; clinicians adapt per patient. Purpose: improve cholestasis, symptoms, and possibly stone formation. Mechanism: replaces more toxic bile acids, protects cholangiocytes, promotes bile flow. Side effects: diarrhea, weight gain, rare liver test changes. Evidence: FDA label (URSO/Actigall). FDA Access Data+1

2) Piperacillin-tazobactam (empiric IV for moderate–severe cholangitis).
Class: antipseudomonal penicillin + β-lactamase inhibitor. Dose (adult typical): 3.375–4.5 g IV q6–8h adjusted to renal function. Purpose: broad Gram-negative/anaerobe coverage while awaiting cultures. Mechanism: cell-wall inhibition with β-lactamase protection. Side effects: hypersensitivity, renal considerations, C. difficile. Label evidence: FDA. FDA Access Data+1

3) Ceftriaxone (empiric/targeted IV).
Class: 3rd-generation cephalosporin. Dose: 1–2 g IV daily (adjust per severity/setting). Purpose: strong Gram-negative coverage; often combined with metronidazole if anaerobes suspected. Mechanism: cell-wall inhibition. Side effects: biliary sludging, diarrhea, hypersensitivity. Label evidence: FDA. FDA Access Data+1

4) Ciprofloxacin (with or without metronidazole for intra-abdominal infection).
Class: fluoroquinolone. Adult label use: complicated intra-abdominal infections (with metronidazole). Dose: 400 mg IV q12h or 500–750 mg PO q12h (renal adjust). Purpose: oral step-down or IV option based on cultures. Mechanism: DNA gyrase/topoisomerase inhibition. Side effects: tendinopathy, QT prolongation, CNS effects. Label: FDA. FDA Access Data+1

5) Metronidazole (anaerobic coverage).
Class: nitroimidazole. Dose: 500 mg IV/PO q8–12h (per label/indication). Purpose: add when anaerobes suspected or in combination regimens. Mechanism: DNA strand breakage after nitro-reduction. Side effects: metallic taste, neuropathy with prolonged use, disulfiram-like reaction. Label: FDA. FDA Access Data+1

6) Meropenem (severe sepsis or ESBL risk).
Class: carbapenem. Dose: 1 g IV q8h (extended infusion per stewardship). Purpose: broad coverage when resistant organisms are likely. Mechanism: cell-wall synthesis inhibition. Side effects: seizures (rare), GI upset. Label: FDA. FDA Access Data+1

7) Ampicillin-sulbactam.
Class: aminopenicillin + β-lactamase inhibitor. Dose: 3 g IV q6h (renal adjust). Purpose: community-acquired biliary infections where coverage fits local patterns. Mechanism: cell-wall inhibition with inhibitor protection. Side effects: allergy, GI upset, transaminase rise. Label: FDA. FDA Access Data+1

8) Levofloxacin (alternative fluoroquinolone).
Class: fluoroquinolone. Dose: 500–750 mg IV/PO daily (renal adjust). Purpose: oral step-down if cultures allow and risks acceptable. Mechanism/side effects: like ciprofloxacin (tendon, QT, CNS warnings). Label: FDA. FDA Access Data+1

9) Cholestyramine (for cholestatic pruritus).
Class: bile acid sequestrant (powder). Dose commonly used: 4 g 1–4×/day, separated from other meds/vitamins. Purpose: first-line antipruritic in cholestasis. Mechanism: binds bile acids in the gut to reduce pruritogens. Side effects: constipation, bloating, fat-soluble vitamin malabsorption—adjust supplementation. Guidance: AASLD cholestatic pruritus pearls. AASLD

10) Rifampin (for pruritus unresponsive to cholestyramine; off-label).
Class: pregnane X receptor agonist antibiotic. Dose often used in practice: 150–300 mg twice daily (monitor LFTs and interactions). Purpose: reduces pruritogenic mediators. Mechanism: induces hepatic enzymes altering bile acid metabolism and pruritogens. Side effects: hepatotoxicity, many drug interactions, orange secretions. Label: FDA (drug interactions/risks). Guidance: AASLD PSC guidance includes dosing for refractory pruritus. FDA Access Data+1

11) Naltrexone (for refractory cholestatic pruritus; off-label).
Class: opioid antagonist. Dose often used: 25–50 mg daily, titrate. Purpose: counters endogenous opioid-mediated itch pathways. Mechanism: central and peripheral opioid receptor blockade. Side effects: withdrawal-like symptoms in opioid users, nausea. Guidance: AASLD PSC practice guidance. AASLD

12) Sertraline (adjunct for refractory pruritus; off-label).
Class: SSRI. Dose often used: 75–100 mg/day. Purpose: may reduce itch perception and improve sleep/mood in chronic cholestasis. Mechanism: central serotonergic modulation. Guidance: AASLD pearls. AASLD

13) Vitamin D (cholecalciferol) supplementation.
Class: fat-soluble vitamin. Dose: individualized to serum 25-OH-D; often 800–2000 IU/day or higher under supervision. Purpose: bone protection in cholestasis. Mechanism: improves calcium absorption and bone mineralization. Risks: hypercalcemia if excessive. Guidance: AASLD nutrition/pruritus guidance. AASLD

14) Vitamin K (phytonadione) before procedures if INR high from cholestasis.
Class: fat-soluble vitamin. Dose: e.g., 5–10 mg SC/IV per clinician (per guidance). Purpose: correct coagulopathy and reduce procedure bleeding. Mechanism: restores γ-carboxylation of clotting factors. Guidance: EASL cholestasis management. EASL-The Home of Hepatology.

15) Vitamin A, E supplementation (water-miscible forms as needed).
Class: fat-soluble vitamins. Dose: individualized to levels and age. Purpose: prevent night blindness (A) and neuropathy/hemolysis (E) from deficiency in cholestasis. Mechanism: replace low stores due to malabsorption. Guidance: AASLD/EASL. PubMed Central+1

16) Calcium (with vitamin D) for bone protection.
Class: mineral supplement. Dose: commonly 1000–1200 mg/day total (diet + pills). Purpose: osteoporosis prevention; especially with cholestasis or steroids. Mechanism: provides substrate for bone. Guidance: AASLD pearls. AASLD

17) Antibiotic step-down per cultures (e.g., amoxicillin-clavulanate if susceptible).
Class: β-lactam/β-lactamase inhibitor. Dose: per label and renal function. Purpose: complete therapy orally after stabilization. Mechanism: cell-wall inhibition. Note: choose agent by susceptibilities. Guideline anchor: Tokyo antimicrobial recommendations. Darmzentrum Bern

18) Targeted antipseudomonal therapy when indicated (e.g., ciprofloxacin, piperacillin-tazobactam, meropenem based on culture).
Purpose/mechanism/risks: as above; tailor to isolate and stewardship. Guideline anchor: TG18 and ASGE statements on early ERCP + appropriate antibiotics. PubMed+1

19) Itch adjuncts (non-sedating antihistamines) for sleep support.
Class: H1 blockers. Purpose: improve sleep/pruritus perception (limited effect on cholestatic itch). Mechanism: central sedation and itch modulation. Guidance: AASLD pearls (supportive). AASLD

20) Prophylactic antibiotics around high-risk procedures (case-by-case).
Purpose: reduce post-ERCP cholangitis if incomplete drainage is expected. Mechanism: transient coverage during instrumentation. Guidance: endoscopy society statements. www.asge.org

---

Dietary molecular supplements

1) Water-miscible fat-soluble vitamins (A, D, E, K).
Dose: individualized to labs (A/E often in water-miscible formulations; D 800–2000 IU/day typical; K per INR/bleeding risk). Function: correct deficiencies from cholestasis. Mechanism: overcome bile-dependent fat absorption barriers. PubMed Central+1

2) Calcium (1000–1200 mg/day total).
Function: bone mineralization with vitamin D. Mechanism: provides substrate while vitamin D enhances absorption. AASLD

3) Medium-chain triglycerides (MCT).
Dose: dietitian-guided inclusion in meals. Function: easier energy absorption when fat malabsorption exists. Mechanism: MCTs are absorbed directly via portal vein and less dependent on bile acids. PubMed Central

4) Zinc (if deficient; dose per lab).
Function: supports taste, wound healing, immunity; can be low in chronic liver disease. Mechanism: replace low stores. AASLD

5) Omega-3 fatty acids (as tolerated).
Function: may aid triglyceride control and inflammation balance; use diet-first approach. Mechanism: incorporation into cell membranes alters eicosanoid profile. (General hepatology nutrition guidance.) Hepatology Journal

6) Selenium (if deficient; dose per lab).
Function: antioxidant enzyme cofactor. Mechanism: supports glutathione peroxidase systems. (Hepatology nutrition texts.) AASLD

7) Folate & B-complex (as needed).
Function: correct anemia or neuropathy contributors. Mechanism: coenzymes for DNA synthesis and nerve health. (General hepatology nutrition practice.) Hepatology Journal

8) Probiotics during/after antibiotics (strain and product quality vary).
Function: reduce antibiotic-associated diarrhea risk. Mechanism: microbiome support; evidence moderate and product-specific. (General evidence; not Caroli-specific.) Hepatology Journal

9) Protein supplements if sarcopenia risk.
Function: preserve lean mass (goal 1.2–1.5 g/kg/day protein unless contraindicated). Mechanism: supplies essential amino acids to counter catabolism. Hepatology Journal

10) Water and oral rehydration solutions during illness.
Function: maintain bile fluidity and perfusion. Mechanism: prevents thick bile and hypotension during infections. PubMed

---

Immunity-booster / Regenerative / Stem-cell drugs

There are no FDA-approved stem-cell or regenerative drugs for Caroli disease, and no “immunity-boosting” medicines proven to prevent cholangitis in this condition. Using unproven cell therapies may be harmful. Care should focus on vaccination, nutrition, and guideline-directed antibiotics and procedures. If transplant is indicated, standard post-transplant immunosuppression is individualized by the transplant center. NCBI+1

1) Vaccinations (HAV/HBV, routine adult vaccines). Indirectly “boosts” protection against preventable infections in a vulnerable liver. NCBI
2) Nutrition + vitamins (A, D, E, K; calcium). Supports immune and barrier function where deficiencies exist. PubMed Central
3) Antipruritic ladder (cholestyramine → rifampin/naltrexone/sertraline). Improves quality of life; not immune-boosting, but reduces symptom burden. AASLD+1
4) Targeted antibiotics for documented infections. Evidence-based infection control—not prophylactic “immune drugs.” Darmzentrum Bern
5) Transplant immunosuppression (post-OLT). Standard regimens (e.g., tacrolimus-based) are used after transplant; not disease-preventive beforehand. BioMed Central
6) Avoid unproven stem-cell offerings. No approved indication for Caroli disease. NCBI

---

Surgeries / procedures

1) ERCP with sphincterotomy and stone extraction.
Procedure: endoscope through the mouth into the duodenum; a small cut in the bile duct opening; stones/sludge removed with balloons/baskets; a plastic stent may be placed if clearance is incomplete. Why: relieve obstruction and stop cholangitis. Evidence/guidelines: ERCP is standard for ductal stones and cholangitis; early ERCP improves outcomes. www.asge.org+1

2) ERCP plastic stent placement and scheduled exchange.
Procedure: insert a temporary stent to bypass narrowed segments; exchange every 3–6 months. Why: maintain drainage when full extraction is not feasible initially. Esge

3) Percutaneous transhepatic biliary drainage (PTBD).
Procedure: radiologist places a catheter through the skin into dilated ducts. Why: alternative drainage when ERCP is not possible or anatomy is complex. www.asge.org

4) Hepatic resection (segmentectomy/lobectomy).
Procedure: remove localized diseased liver segments with the widest, infected ducts. Why: curative for localized Caroli disease to stop recurrent infections and lower local cancer risk. orpha.net

5) Orthotopic liver transplantation.
Procedure: replace the entire liver. Why: diffuse disease with recurrent cholangitis, portal hypertension, or failure; improves survival. BioMed Central

---

Preventions

1. Early care for fever/jaundice—follow the cholangitis pathway. PubMed

2. Keep stent exchange appointments (3–6 months). Esge

3. Hydration, especially during illness or heat. PubMed

4. Vaccinate for HAV/HBV and stay current on routine vaccines. NCBI

5. Nutrition with vitamins A/D/E/K and bone protection. PubMed Central

6. Avoid unnecessary ERCP—use MRCP/US for diagnosis; reserve ERCP for therapy. SGGSSG

7. Antibiotic stewardship—culture-guided, shortest effective courses. Darmzentrum Bern

8. Regular surveillance imaging to watch for complications or masses. PubMed Central

9. MDT follow-up (hepatology/endoscopy/surgery/transplant). orpha.net

10. Education on alarm signs and when to go to hospital. PubMed

---

When to see doctors

Seek urgent care for fever with chills, new or deeper jaundice, right-upper-quadrant pain, confusion, low blood pressure, or rigors—these suggest acute cholangitis, which can become sepsis if not drained quickly. Routine clinic visits should cover symptoms, weight changes, itch, nutrition, vitamin levels, bone health, and any new imaging findings. Discuss surgery or transplant early if infections keep returning or if there is portal hypertension (Caroli syndrome). PubMed+1

---

What to eat and what to avoid

Eat: small, frequent, balanced meals rich in protein; fruits/vegetables; whole grains; water-miscible A/D/E/K if prescribed; calcium + vitamin D for bones; MCT-containing foods/oils if fat malabsorption is an issue (with a dietitian’s plan). PubMed Central+1

Avoid/limit: very fatty or fried meals if they worsen steatorrhea; excessive alcohol; raw/unsafe foods when you’ve had recent biliary procedures or antibiotics; over-the-counter herbal “liver cleanses” without evidence; and missed meals (catabolism). Always separate cholestyramine from other meds and vitamins by several hours. AASLD

---

Frequently asked questions

1) Is Caroli disease the same as Caroli syndrome?
No. Caroli disease = duct dilatation alone; Caroli syndrome = duct dilatation plus congenital hepatic fibrosis/portal hypertension. NCBI+1

2) Why do infections keep coming back?
Widened ducts slow bile, allowing stones/sludge and bacteria to persist; drainage and stone clearance break this cycle. NCBI

3) Do all patients need surgery?
No. Localized disease may benefit from resection; diffuse disease or advanced complications may need transplant; many benefit from endoscopic and medical care alone. orpha.net+1

4) How high is the cancer risk?
Across cohorts, cholangiocarcinoma occurs in roughly ~6–7% of patients; risk varies. Surveillance and definitive surgery/transplant lower risk. PubMed Central+1

5) Can ursodiol cure Caroli disease?
No; it may improve bile composition and symptoms but does not reverse abnormal duct anatomy. FDA Access Data

6) Is there a stem-cell cure?
No approved stem-cell therapy exists for Caroli disease. Avoid unproven treatments. NCBI

7) How often should stents be changed?
Every 3–6 months is commonly recommended to prevent occlusion and cholangitis. Esge

8) What imaging is best?
Ultrasound is a start; MRCP maps ducts without radiation; ERCP is for therapy, not routine diagnosis. JAJ Gastro Hepato+1

9) Which antibiotics are used for cholangitis?
Regimens follow Tokyo Guidelines and local resistance: e.g., piperacillin-tazobactam, ceftriaxone ± metronidazole, or carbapenems for resistant organisms, then culture-guided step-down. Darmzentrum Bern

10) Can diet prevent attacks?
Diet cannot change duct anatomy; good hydration, adequate protein, and vitamin support help resilience and reduce complications from malnutrition. Hepatology Journal

11) Do I need vitamin supplements?
Often yes—A, D, E, K may be low in cholestasis; dosing is based on blood tests. PubMed Central

12) What about itching?
Start with skin care; cholestyramine first-line; rifampin, naltrexone, or sertraline for refractory cases under supervision. AASLD

13) How is severe cholangitis treated?
Urgent fluids + broad IV antibiotics + early ERCP/PTBD for drainage. PubMed

14) When is transplant considered?
Refractory infections, portal hypertension/complications, or liver failure in diffuse disease—transplant markedly improves survival. BioMed Central

15) Can Caroli disease affect the kidneys?
Yes; associations exist with renal cysts and with Caroli syndrome, so kidney function is monitored, especially around transplant. Genetic and Rare Diseases Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 12, 2025.

PDF Documents For This Disease Condition References